Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose escalation of Xentuzumab in Japanese patients with advanced solid tumors
NCT02145741Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2014
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of xentuzumab in solid tumor (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jun 2014; status: completed.
02
Drugs
xentuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02145741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145741.